LuciLorla

Lorlatinib

,

Description

EACH FILM-COATED LUCILORLA TABLET CONTAINS: 

Lorlatinib……………………100mg

 

INDICATION:  

LuciLorla is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

 

DOSAGE AND USE:

Recommended dosage: 100 mg orally once daily.

Severe Renal Impairment: 75 mg orally once daily.

Tablets should be swallowed whole & not chewed or crushed.

 

STORAGE: 

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

 

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

 

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

Reviews

There are no reviews yet.

Be the first to review “LuciLorla”

Your email address will not be published. Required fields are marked *